Basf Aktiengesellschaft

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Helen L Twigger

Paul Rafferty

Lee Daniel Arnold

Gavin C Hirst

David J Calderwood

Rainer Munschauer

David N Johnston

Kurt Ritter

Hormoz Mazdiyasni

David John Calderwood

Stephen St Gallay

Bojuan B Deng

Gerald B Tometzki

Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

4-aminopyrrolopyrimidines as kinase inhibitors

The present application is directed to a compound of Formula (I) as defined herein which are useful as kinase inhibitors.

Kinase inhibitors as therapeutic agents

Compounds of formula I ##STR1## including pharmaceutically acceptable salts thereof in which R.sub.1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, a C.sub.5-7 cycloalkenyl group or an (optionally substituted phenyl)C.sub.1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula OR.sub.A in which R.sub.A represents H or a C.sub.1-6 alkyl group provided that a group of formula OR.sub.A is not located on the carbon attached to nitrogen;

Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors

Growing community of inventors

Nottingham, United Kingdom

Helen L Twigger